Orchard Therapeutics Limited has agreed a rebate with health insurers in Germany for its one-off gene therapy, Libmeldy (atidarsagene autotemcel), for the treatment of metachromatic leukodystrophy (MLD). The company’s chief commercial officer, Braden Parker, shed some light on the agreement and what the company plans to do next to get Libmeldy to patients.
After negotiations with the GKV-SV, which represents statutory insurers, the company secured a discount of around 14% on the original list price, bringing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?